RB

Rishi Bhatia

Active Director Director DIN 02385523
DIN 02385523 First appointment Nov 2008 Primary industry Pharma
Unlock full profile Investments · shareholding · contact details
Current companies 5 active board seats
Past companies 2 historical roles
Total affiliations 7 Since Nov 2008
Shareholding value •••• Premium profile

About Rishi Bhatia

Data last updated:

Rishi Bhatia is a Director at Tppl Pharmaceuticals Private Limited (since 2011), Director at Nivstark Healthcare Private Limited (since 2022) and Designated Partner at Bybv Nutra Llp (since 2023), and holds 2 more current directorships. The companies operate in Pharma and Business Services. The 2 current companies with reported revenue have a combined latest revenue of ₹7.47 Cr; the largest is Tppl Pharmaceuticals Private Limited at ₹6.69 Cr (FY 2025). Earlier, Rishi Bhatia was a Director at Tycoon Pharmaceuticals Private Limited (2008–2013) and Director at Nutrica Nutraceuticals Private Limited (from 2014).

DIN 02385523
Primary Designation Director
Industry Pharma
First Appointment 01 Nov 2008
Oldest Company Age 14 yrs
Largest company Tppl Pharmaceuticals Private Limited · ₹6.69 Cr (FY 2025)
Combined revenue ₹7.47 Cr across 2 companies

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Tppl Pharmaceuticals Private Limited U24232RJ2011PTC037198
Director01 Dec 20112011₹6.69 Cr (FY 2025)Active
Nivstark Healthcare Private Limited U51909RJ2021PTC078170
Director21 Mar 20222021₹78.6 Lakh (FY 2023)Active
Bybv Nutra Llp ACD-6176
Designated Partner26 Oct 20232023Active
Nutristark Llp AAP-6802
Designated Partner19 Jun 20192019Active
Designated Partner31 Oct 20172017Active

Previous companies

CompanyDesignationAppointmentFoundedRevenueStatus
Director01 Nov 20082002Active
Director06 Feb 20142014Strike Off

Explore Director's current and past company associations Uncover their professional journey today!

Directorship timeline

Open interactive timeline →
Nutristark Llp
Tppl Pharmaceuticals Private Limited
Nutrica Nutraceuticals Private Limited
Nivstark Healthcare Private Limited
Premium access

Shareholding and investment profile for Rishi Bhatia

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Rishi Bhatia

Rishi Bhatia currently holds 5 directorships: Tppl Pharmaceuticals Private Limited (Director, since 01 Dec 2011, revenue ₹6.69 Cr (FY 2025)); Nivstark Healthcare Private Limited (Director, since 21 Mar 2022, revenue ₹78.6 Lakh (FY 2023)); Bybv Nutra Llp (Designated Partner, since 26 Oct 2023); Nutristark Llp (Designated Partner, since 19 Jun 2019); Urostark Healthcare Llp (Designated Partner, since 31 Oct 2017).

Rishi Bhatia was first appointed on 01 Nov 2008 as Director at Tycoon Pharmaceuticals Private Limited. The most recent appointment on record is 26 Oct 2023 at Bybv Nutra Llp.

The 2 current companies of Rishi Bhatia that report revenue have a combined latest revenue of ₹7.47 Cr: Tppl Pharmaceuticals Private Limited ₹6.69 Cr (FY 2025); Nivstark Healthcare Private Limited ₹78.6 Lakh (FY 2023).

Rishi Bhatia held 2 earlier board appointments: Tycoon Pharmaceuticals Private Limited (Director, 01 Nov 2008 to 01 Oct 2013); Nutrica Nutraceuticals Private Limited (Director, from 06 Feb 2014).

The current boards of Rishi Bhatia's companies include Manohar Lal Chhabra (Tppl Pharmaceuticals Private Limited), Vivek Bansal (Tppl Pharmaceuticals Private Limited), Pratibha Sharma (Nivstark Healthcare Private Limited), Pravesh Sidana (Nivstark Healthcare Private Limited), Suman (Nivstark Healthcare Private Limited), Nishad Sharma (Bybv Nutra Llp), among others.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available